ATE359998T1 - Kleine technetium-99m und rhenium markierte mittel und verfahren zum tumor-imaging - Google Patents

Kleine technetium-99m und rhenium markierte mittel und verfahren zum tumor-imaging

Info

Publication number
ATE359998T1
ATE359998T1 AT01948207T AT01948207T ATE359998T1 AT E359998 T1 ATE359998 T1 AT E359998T1 AT 01948207 T AT01948207 T AT 01948207T AT 01948207 T AT01948207 T AT 01948207T AT E359998 T1 ATE359998 T1 AT E359998T1
Authority
AT
Austria
Prior art keywords
technetium
tumors
complexes
methods
imaging
Prior art date
Application number
AT01948207T
Other languages
German (de)
English (en)
Inventor
Ashfaq Mahmood
Matthais Friebe
Christina Bolzati
Alun G Jones
Alan Davison
Original Assignee
Harvard College
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Massachusetts Inst Technology filed Critical Harvard College
Application granted granted Critical
Publication of ATE359998T1 publication Critical patent/ATE359998T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/41Y being a hydrogen or an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005Compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01948207T 2000-04-28 2001-04-27 Kleine technetium-99m und rhenium markierte mittel und verfahren zum tumor-imaging ATE359998T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20063300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
ATE359998T1 true ATE359998T1 (de) 2007-05-15

Family

ID=22742530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948207T ATE359998T1 (de) 2000-04-28 2001-04-27 Kleine technetium-99m und rhenium markierte mittel und verfahren zum tumor-imaging

Country Status (8)

Country Link
US (2) US7321027B2 (enExample)
EP (1) EP1276718B1 (enExample)
JP (1) JP5186075B2 (enExample)
AT (1) ATE359998T1 (enExample)
AU (2) AU6968301A (enExample)
CA (1) CA2407592C (enExample)
DE (1) DE60127951T2 (enExample)
WO (1) WO2001083436A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515131B2 (en) 2000-02-22 2003-02-04 Biostream Therapeutics, Inc. Imagining agents for diagnosis of Parkinson's disease
WO2004043380A2 (en) * 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
JP2009051784A (ja) * 2007-08-28 2009-03-12 Inst Nuclear Energy Research Rocaec 癌を抑制する放射性物質及びその調整方法
WO2010144891A1 (en) * 2009-06-13 2010-12-16 President And Fellows Of Harvard College Compositions and methods for imaging tissues, organs and tumors
US10550139B2 (en) 2014-06-09 2020-02-04 Triad National Security, Llc Polydentate ligands and their complexes for molecular catalysis
WO2015191505A1 (en) * 2014-06-09 2015-12-17 Los Alamos National Security, Llc Polydentate ligands and their complexes for molecular catalysis
WO2015200187A1 (en) 2014-06-27 2015-12-30 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
WO2017019664A1 (en) 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions and methods of treating cancer
WO2017223428A1 (en) 2016-06-24 2017-12-28 Cornell University Rhenium complexes and methods of use for treating cancer
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US10487100B1 (en) 2017-04-04 2019-11-26 Triad National Security, Llc Macrocyclic ligands and their complexes for bifunctional molecular catalysis
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023009442A1 (en) * 2021-07-26 2023-02-02 Rapid Therapeutic Sciences Laboratories, Inc. Improved process for ph-balanced cbg (# 10)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4638051A (en) * 1984-04-30 1987-01-20 The Johns Hopkins University Brain imaging radiopharmaceuticals
ZA852981B (en) * 1984-04-30 1985-11-27 Univ Johns Hopkins Brain imaging radiopharmaceuticals
US5136038A (en) * 1984-07-19 1992-08-04 University Of Florida Radiopharmaceuticals and chelating agents useful in their preparation
ZA863205B (en) * 1985-05-01 1987-08-26 Univ New York State Res Found Diagnostic radiopharmaceutical compounds
JPH02180865A (ja) * 1987-12-29 1990-07-13 Nippon Mejifuijitsukusu Kk キレート形成性化合物とその用途
AU3778989A (en) * 1988-04-29 1989-11-29 Mallinckrodt, Inc. Diaminedithiol chelating agents for radiopharmaceuticals
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
DE60127951D1 (de) 2007-05-31
WO2001083436A2 (en) 2001-11-08
AU6968301A (en) 2001-11-12
EP1276718B1 (en) 2007-04-18
JP2004501093A (ja) 2004-01-15
US20080226550A1 (en) 2008-09-18
AU2001269683B2 (en) 2006-12-21
US7321027B2 (en) 2008-01-22
JP5186075B2 (ja) 2013-04-17
DE60127951T2 (de) 2008-01-17
EP1276718A2 (en) 2003-01-22
WO2001083436A3 (en) 2002-06-20
US20040097735A1 (en) 2004-05-20
CA2407592C (en) 2011-03-22
CA2407592A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
ATE359998T1 (de) Kleine technetium-99m und rhenium markierte mittel und verfahren zum tumor-imaging
DE60329274D1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
Price et al. H4octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy
Nichols et al. 68 Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers
WO2002087498A8 (en) Diagnostic imaging compositions, their methods of synthesis and use
DE60238143D1 (de) Zusammensetzungen und verfahren für die diagnose von tumoren
ATE401575T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
NO20015991D0 (no) Bisykliske polyaminoacid-metallkomplekser, fremgangsmåter for fremstilling av disse og anvendelse i medisinsk billeddannelse
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
IL175667A (en) Imaging factor that includes a synthetic caspase-3 inhibitor marked with the neuroimaging agent, a radiopharmaceutical containing it, a kit for preparation of the preparation and a method for diagnosis based on it
Li et al. Advances in macrocyclic chelators for positron emission tomography imaging
Knetsch et al. [68Ga] NS3-RGD and [68Ga] Oxo-DO3A-RGD for imaging αvβ3 integrin expression: synthesis, evaluation, and comparison
Li et al. Recent advances on radionuclide labeled hypoxia-imaging agents
Qiao et al. Novel 64Cu-labeled NOTA-conjugated lactam-cyclized alpha-melanocyte-stimulating hormone peptides with enhanced tumor to kidney uptake ratios
WO2004043380A3 (en) Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
ATE556722T1 (de) Herstellung von vierzähnigen peptidchelatkonjugaten zur diagnose von kolorektalem krebs
NO20051811D0 (no) Conjugates of TC complexes and targeting moiettes and their use in mri diagnostic
Larenkov et al. Radionuclide diagnosis of prostate cancer: Positron emission tomography with 68Ga-PSMA inhibitors and their pharmaceutical development
ATE396265T1 (de) Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
EP1581790A4 (en) PEPTIDES WITH HOMING FOR LYMPHOTIC TARTOR AND ITS USE
Kameswaran et al. Preclinical evaluation of 131I-Bevacizumab–A prospective agent for radioimmunotherapy in VEGF expressing cancers
RU2007135882A (ru) Производные фенилоксианилина, меченные радиоактивным галогеном
ID28035A (id) Kegunaan turunan antrasiklin untuk pengobatan tumor hati
Lee et al. Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with 177Lu for potential use in radioimmunotherapy
DE60033697D1 (de) Radiomarkierte vip-analoge zur diagnose und therapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties